Biotech in Is­rael: Hold­ing on to busi­ness as usu­al amid un­cer­tain times

In the mid­dle of our Zoom in­ter­view, Mati Gill, Tel Aviv-based CEO of ven­ture stu­dio AION Labs, ex­cused him­self calm­ly to find shel­ter when a siren start­ed to run amok in the back­ground. Af­ter five min­utes, he re­turned and said: “I have to show an ex­am­ple for the kids — so I can’t skip out on run­ning to the shel­ter.”

Af­ter mil­i­tant group Hamas made at­tacks with thou­sands of rock­ets on Sat­ur­day, Is­rael has since de­clared a state of war. The events prompt­ed words of sup­port from phar­ma in­dus­try fig­ure­heads such as Pfiz­er CEO Al­bert Bourla, with Is­rael-based com­pa­nies such as Te­va re­as­sur­ing ob­servers that it doesn’t an­tic­i­pate an im­pact on its busi­ness and op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER